Good morning, and a very warm welcome to our 2023 results presentation, and my first public engagement since joining as Chair on 19th of February. I would like to start by thanking you for your patience as we endure the number of audit delays. This process has been extremely frustrating for all of us. While it's taken much longer than we anticipated to complete the audit of the 2023 accounts, the delay has allowed us time to implement a thorough review of our processes and perform more detailed work in respect to impairments. This enhanced impairment review is now more robust, and we are working on a plan to ensure we're in a strong position for future audits. I will leave Andrew to explain the reasons behind the delays and the extra scrutiny this year, but you will have noted the number of assets we have impaired. I'm delighted to join Alliance at such an important and exciting time for the company, having spent over 30 years in the consumer industry across publicly listed U.S., European, and Asian companies, and even lived and worked in U.S., Europe, and Latin America. While I'm still building my understanding of the company, I can see several opportunities to boost performance in our key categories, and I look forward to working with management, applying my expertise to help ensure we have the right strategy and structures in place to maximize value. As you will have seen our recent announcement, after nearly 14 years in Alliance, Peter Butterfield has decided it's time for a change, and he will leave the business at the end of this month. After a comprehensive search, Nick Sedgwick was appointed CEO and joined Alliance on 13th of May. Nick has 30 years of experience in consumer health with a number of European, US, and global roles, a large multinational such as Reckitt and Coty. We're extremely grateful for everything that Peter has done for Alliance and wish him well in his future endeavors. Nick joins us in the room today, and, as he only has been in the business for about a month, we thought it would have been a little unfair to make him present the 2023 results. However, once he had time to deepen his understanding, we will work together with the wider leadership team to refine the longer-term strategy, and we'll provide an update to the market in due course. Finally, I would like to congratulate the team at Alliance for the successful appeal of the Competition and Markets Authority's decision in relation to anti-competitive behavior. The company has always strongly denied the allegations, so it's great to have such an unequivocal decision from the Competition Appeal Tribunal panel, completely exonerating Alliance and their directors named in the case from all wrongdoing. As a result, we have reversed the GBP 7.9 million provisions for the potential fine, which we booked in 2021. Today, in addition to Nick, I'm pleased to be joined by Andrew Franklin, Jeyan Heper, and Cora McCallum. Andrew will take you through an overview of 2023 performance, and then Jeyan will provide more details on our key brands before handing back to Andrew to go through the financial results. We will then open the questions from the room and from those listening to the webcast. Over to you, Andrew. Good morning, and thanks, Camillo. As Camillo has said, the delay in the reporting this year has been extremely frustrating and unhelpful, and this year's audit identified weaknesses in our internal controls environment, particularly around our approach to the valuation of our intangible brands. However, as we've stated throughout, there's been no impact to the underlying performance of the business, either profits or cash. In fact, our free cash flow for 2023 was 35% higher than in the prior year. The delay has allowed us to undertake a thorough review of our processes and to perform more detailed work in our assessment of brand values. And this has highlighted areas in our approach and assumptions used in the FY 2022 valuation for Amberen. We subsequently viewed the carrying value of all of the brands for 2022, and that's resulted in a GBP 28.3 million increase in the impairment charge for that year. That consists of GBP 20 million for Amberen and GBP 8.3 million for other assets, including the Flama franchise. For those who undertake DCF valuations, you know the large range of variables and assumptions used in any calculation. When you multiply this over our broad portfolio of products, you can imagine the amount of work that's had to be covered by the finance team and also by Deloitte over the past months. I'd like to thank the finance team for staying the course. It has been a huge team effort from which we will emerge stronger. Throughout this process, we've worked collaboratively with the team at Deloitte with the sole purpose of getting the accounts correct and improving our processes, which we have done and will continue to do so to ensure that future delays in our reporting do not happen going forward. Turning to 2023, our impairment review process led to further non-cash items of GBP 79.3 million, which includes a further impairment charge for Amberen of GBP 46.4 million and a charge for Nizoral of GBP 10.3 million. While both Amberen and Nizoral remain profitable and cash-generative assets, these non-cash impairment charges reflect a reassessment of expected future cash flows, taking into account product launches, cost estimates, marketing spend, and such like, together with an overall increased cost of our borrowings as well. The remaining impairment charge of posted in 2023, of GBP 22.6 million, relates to other products in the portfolio, including Vamousse and Optiflo. It is driven by changes in the financial outlook, for instance, the impact of stock outs and changes in regulatory framework together, and with an overall increase in our WACC. Other non-underlying items in the year comprise the annual amortization charge of GBP 7.2 million, which is in line with the charge last year. As Camillo has just mentioned, we announced on the 23rd of May, the Competition Appeal Tribunal's position, where they upheld Alliance's appeal and unanimously agreed that there was no breach of competition law, which is just a superb result. As a result of this, we're able then to reverse the provision we had for the fine, potential fine of GBP 7.9 million. Now, focusing on 2023, I'm very pleased with the result, the record revenue growth that we had, up 6% versus the prior year, with a particularly strong performance in the second half. Sales of Kelo-Cote rebounded, rebounded strongly, with a 29% revenue growth, adjusting for currency over the full year, following a slower start at the beginning. Nizoral delivered a solid performance as we took full control of the brand, but Amberen is still below expectations as we continue to manage the transition from bricks and mortar to e-commerce. Our other consumer healthcare brands delivered another strong year of excellent organic growth, demonstrating the value of our diversified strategy. With our prescription medicines, business continued to provide a stable income growth. These two segments were impacted by some stock outages in the first half of the year, but all affected products are now back in stock, and Jeyan will talk more about this in his section. We also worked hard to ensure the business remains positioned to deliver sustainable growth in the longer term. The first full year of our US acquisition of ScarAway was a great success. We launched award-winning marketing campaigns to widen the reach across our brands, and perhaps most pleasingly of all, we doubled revenues from products launched through our own internal development pipeline. At Alliance, people are fundamental to our success, and we continue to invest in our colleagues, and we created new roles across all geographies to meet the evolving needs of the business. We also welcomed our second cohort of graduates and year in industry programs, while also strengthening our executive team and board, adding 3 new non-execs to the board and appointing a new chair, Camillo, and Nick as CEO in the first half of this year. We've been recertified as a great place to work in the U.K., U.S., China, and Singapore, and the development of our ERP platform continues with a successful rollout in APAC in last year, in 2023, and we're now poised to launch in China in the second half this year. Once live in China, our ERP system will be complete across the Alliance portfolio and platforms. We also consolidated our Nizoral manufacturing in Asia, moving from the J&J site in Belgium to one of our established partners in Thailand. This will have multiple benefits, including lower cost of goods, bringing production closer to customers, which also improves order delivery and reduces our carbon emissions. Turning to financials, I'm pleased that our robust control of cost meant that 6% revenue growth translating to a 15% EBITDA growth in the period. This supported our ability to generate cash in the year with a 35% increase in free cash flow to over GBP 21 million, despite higher interest payments. This cash flow allowed us to reduce our net debt by GBP 11 million, and I'll cover this in more detail later. I will also update you on the refinancing of our revolving credit facility, which we completed in August last year. We also continued to make good progress on our sustainability journey. Last year, we set our target to reach net zero Scope 1 and 2 emissions by 2030, with an interim reduction of 65% by 2025. I'm pleased to report that we're well on track with a 48% reduction by the end of 2023 relative to our 2018 baseline, and we've invested in carbon offset products to achieve carbon neutrality last year. We have just completed the installation of PV panels on our roof in our UK headquarters. When these are operational, we expect to generate some 25% of our own electricity needs, further reducing our Scope 1 and 2 emissions. This year, we set a new target to be net zero for our Scope 3 emissions by 2044, with an interim reduction of 25% by 2030 relative to our 2022 baseline. So I think you can say we've made some really strong progress with our ESG agenda. Throughout 2023, we progressed social and governance strategies as well, partnering with the Slave-Free Alliance to ensure our values extend throughout our supply chain. We've secured greater compliance with our partner code of conduct. We've introduced a new employee code of conduct, both of which are available on our website. Now, let me hand over to Jeyan, who will talk you through the performance of our key brands, the challenges we faced last year, and the actions we have in place to drive growth this year and beyond. Jeyan? Thank you, Andrew. Today, I will be taking you through the performance of our key brands, starting with Kelo-Cote franchise. We are rightly proud of our Kelo-Cote franchise. Kelo-Cote is the leading silicone scar treatment brand globally, with 11% market share. Our extensive product portfolio consists of gels, sprays, sheets, and a dedicated formulation for kids, all of which are now available in the U.S. under the ScarAway brand, which we acquired in March 2022. With a global footprint, we can really lean into our marketing, making use of key opinion leaders and to drive our brand forward. Kelo-Cote franchise revenues grew 29% at constant revenue in 2023. This slide shows the progress we have made over the last six years. Remember when we acquired Kelo-Cote from Sinclair in 2015, it had revenues of GBP 8 million per annum. We have delivered consistent franchise revenue growth since, with 23% revenue CAGR between 2018 and 2023. You will note the growth in other territories as we leverage our global position and increase consumer awareness. US sales benefits from the full 12 months of ScarAway, versus only 9 months in 2022, and we continue to deliver strong growth in the domestic market in China as our distributor accesses new channels. In the China cross-border channel, we saw growth through further expansion of the business-to-consumer channel and recovery in business-to-business. Our strategy is to prioritize our efforts and resource on e-commerce channels, and we had a very successful Singles' Day festival in November, the Chinese equivalent of Black Friday, in which we increased in-market sales by 197% versus the same period prior year. We remain focused on e-commerce channels, which are more strictly regulated, and through which we have much greater control, while optimizing our presence in the physical markets and maintaining brand protection efforts here. Let's focus on domestic China. The e-commerce part of this market generates total annual revenues of around GBP 100 million. Kelo-Cote is the market leader with 23% share, up four percentage points on the same period in the prior year. We are seeing the market consolidate, with smaller players losing share to major brands. Yet still, some 57% of the market is comprised of other brands, which allows us plenty of opportunities to grow market share further. The kids formulation has been a really important contributor to our success and growth, and it has helped expand the market rather than cannibalize existing sales. We expect to drive further growth by leaning into e-commerce opportunity, supported by new product introductions. Turning to cross-border, the latest data shows that e-commerce sales in cross-border totaled nearly GBP 25 million in the year. Again, Kelo-Cote has a market-leading position with 51% share, relatively flat on last year. As I mentioned earlier, we are seeing strong growth in business-to-consumer channel. We have worked closely with Ali platforms to optimize marketing keywords, and through implementing learnings from the recent 618 shopping festival in June, we delivered a very strong performance during the Singles' Day in November. We have optimized our content across all cross-border e-commerce platforms to increase our in-store conversion rate. We are delighted that Kelo-Cote is the leading brand in scar treatment sales on the Tmall platform. Turning to the U.S. market, which is the second-largest scar market, scar treatment globally, and it is worth some $90 million in end-user sales, with ScarAway commanding a market share of 26%, the second biggest brand behind Mederma. We were particularly pleased with the acquisition and integration. We recognized an opportunity to return some discontinued SKUs to market and delivered sales above original expectations in our first full year of ownership. In 2024, we expect to launch in Canada and have a number of range of extensions in our innovation and development pipeline. Now that we have the worldwide rights to Kelo-Cote, we can build brand awareness globally. We currently sell Kelo-Cote in 67 countries. The countries on this slide represent our major Kelo-Cote franchise businesses globally. Our focus for 2024 is to further build brand and scar treatment category awareness, as our research shows a considerable growth opportunity remains within our core range. In 2024, we rolled out new global creative, which we have developed in conjunction with Saatchi & Saatchi Wellness. Digital activation remain a key focus for us in 2024 to further stimulate ongoing increases in online purchasing. As we said in the RNS, we intend to move towards smaller, more regular order fulfillment to create a more consistent revenue stream. This is expected to yield mid-single-digit revenue growth for Kelo-Cote franchise in 2024, before returning to double-digit growth from 2025. Turning now to Nizoral, or Titop, as it is known in China. We are really excited about the increased potential for this brand now that we have it under full control across the APAC region. Nizoral is a treatment for severe dandruff, which affects around 3% of the population, creating a market worth some $235 million and growing at 4% per annum. However, growth is forecasted to accelerate to 6% from 2025, as young adults look to improve their personal appearance to be accepted socially and get ahead professionally. Nizoral holds a leadership position in four markets: Australia, South Korea, Thailand, and Japan. It is the third-largest brand in China. In each of these regions, Alliance is working with leading distribution partners who are investing in brand-building activities to target younger consumers. We have introduced new modernized packaging in 2023, featuring a strong claim set, which is again designed to appeal to a younger audience, and are expanding our reach in pharmacy chains and e-commerce channels. We have an exciting pipeline of products focused on the adjacent cosmetic markets. The transfer of manufacturing from Johnson & Johnson's site in Belgium to Thailand completes our transition and gives Alliance end-to-end responsibility over sourcing, manufacturing, and distribution. We are also poised to deliver China's supply security through a second source from mid-2024. As you will have seen from the previous slide, China is our biggest market for Nizoral, representing 44% of sales in 2023. In this market, Titop is the third-largest brand with 7% share, and Kangwang from Bayer is the dominant player. This is a market where we have seen market share eroded during the transition from Johnson & Johnson to Alliance, because we were unable to control and influence the delivery of consumer marketing activation campaigns. However, since early 2023, we have developed and refined new campaigns. Our new out-of-home campaign was launched in August and then supplemented by a second burst in November, yielding strong results, with Q4 revenue up 21% on Q3, for example. We have further initiatives planned in 2024 to expand our reach across pharmacy chains and e-commerce platforms. These include shopper engagement through our in-store scalp test and product sampling in China. We are launching new, larger pack sizes in Taiwan and China to drive higher value baskets, and we will launch a daily use product from the middle of this year to extend consumer use. We will strengthen our marketing this year, targeting a further 20 cities with our consumer activation campaigns. We then see further opportunities in brand expansion into adjacent markets and have a number of innovation projects in our pipeline. We will provide more detail when we bring these products into market. This slide summarizes our plans to activate the brand across APAC, from media campaign to strong distribution partnerships, as well as strong launches across different territories. Turning to Amberen, the US market for menopause relief product, it is valued around $200 million. The market is pivoting rapidly from bricks and mortar to e-commerce. We've already explained that Amberen sales are more weighted to the bricks and mortar channel. However, we have focused our marketing efforts on e-commerce. Amberen has 20% share in bricks and mortar and 7% on Amazon, which accounts for the majority of e-commerce sales on the category. The e-commerce market has expanded rapidly with the new entrants. We have faced a number of challenges in 2023, primarily on Amazon, which we will detail on the next slide. While we're still working to build appropriate capabilities internally, we continue to believe in the long-term growth of the menopause category. We are leaning into e-commerce opportunity while we stabilize our bricks and mortar sales through the prioritization of key retail accounts, through leveraging innovation, and emphasizing our key points of differentiation versus the competition on shelf. We remain focused on building brand awareness through effective campaigns, and we will use our innovation to attract new brand users while increasing penetration with our existing users. While it was disappointing to take a further impairment on Amberen this year, it's worth remembering that the brand remains profitable, and we have made progress to strengthen the brand infrastructure. We have refreshed our direct-to-consumer website, amberen.com, to optimize the consumer experience. Amberen differentiates itself with clear, evidence-based claims, and we reinforce this on the packaging by highlighting that Amberen is a unique formulation that is not available as a store or private label brand. Finally, we developed and launched a gummy formulation, the first in the category. We have a pipeline of second- and third-generation products in development. In fact, this month, we have launched a second gummy in the US for energy, mood, and sleep, and we expect further upgrades and line extensions. However, we rightly acknowledge that sales in 2023 were below expectations, as we faced multiple challenges in the year and continued to build our capabilities to support the brand. The menopause symptom relief market is highly competitive. Sales on Amazon increased significantly, driven by a proliferation of new entrants. Our perimenopause product was delisted for several months, and there was a significant increase in unauthorized sellers, resellers, offering Amberen product at lower prices, causing the loss of Buy Box. The loss of Buy Box has a knock-on end impact, preventing advertising from being executed at scale and preventing new subscriptions. However, we are strengthening our capabilities in e-commerce and digital marketing. We have increased the level of marketing support to revert the brand growth.... We have been focused on addressing the unauthorized reseller issues with the engagement of a new brand protection and legal partner, as well as a security audit team. We have a pipeline range of initiatives and line extensions planned. I also want to take a little time to talk about our next biggest brands, MacuShield and Hydromol, both of which generated GBP 9 million of revenue in 2023, and both of which have the potential for further geographic expansion. MacuShield is a vitamin and mineral supplement to promote eye health. It is currently sold in 21 countries, but the majority of sales are generated in the UK. Revenues grew 1% in 2023. In 2024, we will continue to build our success through healthcare professional recommendation, and in those markets where we have established a presence with the healthcare professionals, we will extend our direct-to-consumer activity. We have just launched MacuShield Omega-3 in the UK, and it will be extended to other markets soon. Hydromol is a treatment for eczema, which is currently sold in 4 countries. We delivered 12% growth in 2023, driving record revenues as we partnered with healthcare professionals to raise awareness for the brand within the NHS. As a result, Hydromol ointment is now the ointment of choice across many NHS trusts and has continued to rapidly increase its market share. We have utilized this position to grow the Hydromol cream business, with strong momentum continuing in 2024. With that, I will hand you back to Andrew to go through the financial results in more detail. Thank you. Thank you. So as already mentioned, CER sales increased 6% on a reported basis to GBP 182.7 million, and 7% when adjusting for currency. Gross margin declined due to a revenue mix and higher warehouse and distribution costs, which resulted in a gross margin of 57.5% for the year. We continued our investment in the business over the year, improving our operating capabilities and marketing effectiveness, whilst maintaining good cost control, leading to a reduction in operating costs of 5%. Consequently, EBITDA increased 15% to GBP 45 million, representing a healthy 24.6% to sales. As a result of higher interest rates, our financing costs increased, which meant our underlying profit before tax increased 4% to GBP 31.5 million. But with a reduction in our effective tax rate, underlying basic EPS increased 6% to GBP 0.0455. With strong cash flow from trading, we were able to reduce our debt and lower leverage to 2.05x from 2.57x at the end of 2022. As we detailed in our interim statement released in September, the dividend was paused to allow the board to develop a new dividend policy with a greater emphasis on reinvestment in the business, to drive growth, and to reduce our borrowings. Taking account of shareholder feedback, the board has decided that no dividend will be declared in 2023 and will provide an update on the dividend policy when appropriate. I won't discuss this slide in detail, as Can has covered the performance of asks, of our three key brands. But I do want to highlight the 5% growth in other consumer healthcare products, which includes strong growth from products such as Oxyplastine and Ashton & Parsons, and demonstrates the benefits of our diversified portfolio. Remember that this business did experience regulatory delays in some of our products, which impacted stock availability in the first half of 2023, which has now been resolved. And if we adjust for these out-of-stocks, consumer health would have grown in the mid-teens last year. And as a reminder, the wider consumer healthcare market is anticipated to grow between 5%-7% per annum. Our prescription medicines business continues to deliver stable performance, with revenues of GBP 46 million generated in the year, with Hydromol performing strongly. Sales of prescription medicines were also hampered by some specific regulatory changes, which have also been addressed. Adjusting for these, underlying sales would have grown in the mid-single digit in the prior year. This slide walks through the movement in revenue and underlying profit before tax. Looking at the revenue bridge on the left-hand side, this shows strong performance from our Kelo-Cote franchise and the challenges we faced with Amberen. Sales for 2023 grew 7% at constant currency at GBP 184.8 million, and 6% on a reported basis at GBP 182.7 million. Looking at the right-hand side, where you see the profit before tax bridge, you can see the operating costs were well controlled, decreasing GBP 3.1 million, despite the high inflationary environment we work in. But we also maintained investment in both marketing and headcount to drive further growth. However, these savings were offset by higher interest costs, which reflect, primarily, the increase in interest rate costs. At the end of the year, we ended with a profit before tax of GBP 31.5 million. In the year, we generated cash flow from trading of GBP 36.9 million, and after taking account of working capital outflow of GBP 8.9 million due to timing of sales and cash receipts, which came as we made the high level of sales in the third and fourth quarter. These were largely reversed in the first half of this year. Tax payments of GBP 5.5 million and interest payment of GBP 9.4 million pound results in our cash flow for the year of 31, of 21.3 million pounds, up 35%. The chart on the right-hand side shows the movement in net debt. We started the year with net debt at an elevated level of GBP 102 million following the acquisition of ScarAway in the US, and that had corresponded to a leverage of 2.57x. However, with strong cash flow from trading, we closed the year with net debt of GBP 91.2 million and a leverage of 2.05x. We remain focused on cash flow generation and debt reduction and expect leverage to be below 2x by the end of 2024. As I mentioned earlier, in August, we successfully re-completed the refinancing of our revolving credit facility with the group's existing banks of syndicate of supporting relationship banks. Through the refinancing, we took the opportunity to resize and reduce the total of our committed facility by GBP 15 million, and it now stands at GBP 150 million, whilst increasing the uncommitted accordion by GBP 15 million, and that now moves to GBP 65 million. The covenants include net leverage and interest cover tests. This facility is available until August 2026, with two further one-year extension options. Finally, for those who are interested, and it could be some folks in this room, we've included some technical guidance in the appendix to indicate our expectations for items including tax rate, interest charge, and CapEx. So turning to our summary and outlook, our core products, core priority markets remain competitive, with our key brands well-placed in their categories, and we continue to invest in our, and to maintain their, their leadership position. The majority of this investment will focus on sales and marketing, which will be supplemented by investment from our distributor partners. We'll also double down on innovation development and brand activation. And finally, we must remember that people are our biggest asset, and we worked hard with them to recruit the new talent to make sure, ensure that we continue to the investment in our colleagues this year. As a result, the board anticipates that underlying profits for 2024 will be in line with 2023, and we remain focused on cost-strong cash generation and expect leverage to be below 2x by the end of this year. Thank you for listening. Camillo, Nick, Jay, and I will be very happy to take your questions. Thank you. Hi, thanks for taking my questions. It's Andrew from Investec. Two questions, if I may. Can I just are you able to just to talk to the impairment piece and the cash generation? The cash generation looks really strong. My understanding of accounting is probably that the valuation on the balance sheet is a comment on cash generating units, right? And you, you've impaired some cash generating units there, but the cash is actually very strong at the moment. So how do you square those two, how do you square those two bits? So, as you know, as you rightly say, that if you look at the level of cash generated from these assets, they're extremely cash strong. So we've seen an increase in the discount rate when we've looked at our overall weighted average cost of capital, and that's certainly had an impact. But also, we've looked at the product launches and cost increases that we see coming through. And we've been, I wouldn't say conservative, but we've taken a more appropriate level of where we see that growth coming from. So we're still very confident in those products. They are great in their field and market leading. We've just taken a slightly different view this year. And clearly, Kelo-Cote, there's been no question on Kelo-Cote. It's just around Amberen, and [audio distortion]. Got it. Got it. And because you're at 2.05 on the leverage now, you've said 2 by the end of 2024, but that's probably a, you know, an achievable number? Yeah. Yeah. Okay. That's very helpful. Thank you. And then, is Kelo-Cote, but generally, your key brands, right? Kelo-Cote's your global brand, and you're very strong in some markets. Is the future of Kelo-Cote incremental penetration into those markets that you're already in and doing very well in, or is it about expanding that brand into other territories? And that's across all of the key brands, if I- Specifically for Kelo-Cote, we are selling the brand in 67 markets, but as you know, majority of our sales come through China at this moment. But we experimented in UK, which generated 36%-38% growth in the year. So we are looking into areas where we have potential to further leverage our distribution, partnership, consumer activation, others. So yes, within these 67 markets, we have identified key drivers for Kelo-Cote's future success outside China, UK, and others. And you've seen in our other results, like US, was a major contributor in our first year of full acquisition. We want to further grow US markets ScarAway. There are so many opportunities in the market that we have identified. So yes, I mean, those will all come in 2024 and beyond. Thank you. I guess I should leave it for other people. Thanks. Thanks a lot. Thanks. It's Sam England from Berenberg. Just the first one, you've called out increases to sales and marketing investment in the outlook for 2024. I was just wondering how you're thinking about the margin opportunity in the longer term, and particularly, how you see the sort of trade-off between investment in sales and marketing, driving revenue growth and then margins, which are obviously going to be impacted by that increased investment. So how do you sort of weigh up the investment decision? Overall piece, clearly I look at the overall P&L. And with, and we've already mentioned around the moving into the APAC region for Nizoral, and that's going to help with improved cost of goods and lower warehouse and distribution costs. We should see that gross margin come through, which will then help fund the additional sales and marketing spend that we want to put between those brands. Because obviously, we're looking at both innovation and development, because we want to really turbocharge that pipeline. And I know Jeyan can talk a little bit more about the products that we've launched last year and this year as well. And as we look at the brands, we then work out the level of investment and return that we need, and it's a fluctuating, sort of, fluctuating piece where we know we can get some really good growth coming from in returns. That's where we'll invest, and it may mean that we reduce some of the investment in other brands. But the increase in marketing investment is very much focused on those three star brands. Okay, great. And then, just, just around China, there's obviously been quite a lot of negative commentary year to date, sort of in the news around the consumer environment in China. But you've obviously guided, you know, that performance has been in line in the first five months of the year. So can you just talk a bit about what you're seeing on the ground in the consumer environment in China, which seems maybe a bit at odds with the sort of upbeat outlook around the performance in the China side of the business? Yes, I mean, across China, there are many reports about softening consumer demand, difficulties in certain categories to grow. But for our category, we see still strong consumer in-market demand, and we outperform on that. And this is our priority, and you've seen it in our presentation that we grow market share, and we bring new innovation to consumer. We expand our reach across different platforms. So this is how we leverage the current situation. But for our market also, it is still continuing to grow in China. Great. Thanks very much. Hi, Charles Weston from RBC. Just a question for you first, Camillo, if I can, please. Presumably, you've met with your major shareholders. What is the briefing that they've given you in terms of your sort of strategic view around, you know, how you're driving Alliance Pharma? And when it, when you look at the performance of other consumer, which has been quite strong and quite good over quite a long time, and the volatility or disappointing performance in some of the larger brands, does that change the outlook for a long-term strategic view of Alliance Pharma and bolting on brands? Look, speaking with shareholders, I think, everyone has kind of the same opinion, which is this is overall a good business, right? With strong brands, which work in categories that are growing at a global level, right? If I look at scar treatment, if I look at menopause supplement, eye health, you know, medicated shampoos or dandruff and scalp treatment. And so the shareholders are of the same opinion that we are in the right, in the right business. And looking at the brief, clearly, you know, there is a need of a pay down debt, which is our objectives. And I think, Andrew was quite explicit that in the short term, that's our objective, and that we're gonna focus on that. In the longer term, we're gonna build a company that outgrow the market and grows, right? Grows both from a sales and also from a profit, you know, point of view, so margin expansion and clearly creating shareholder values. This is the objective that the shareholder have, and I completely share their view. So, looking at the, you know, from an assessment point of view, I think that we are in the right business. We just have to probably continue in the same with the same strategy of building a consumer health company. I think, you know, we have already done that from a portfolio point of view. Now, 75% of revenues are consumer health. Probably from a capabilities point of view, we are not there yet, and therefore, one of my objective is to work with management, including new leadership, to ensure that we accelerate those capabilities building, right? Okay, thank you. And then just two smaller questions. First on Kelo-Cote. If you're going to smaller, maybe monthly deliveries rather than two monthly deliveries, I think you might be expecting some reduction in inventories from your, from your distributors. So from where we were, or how many months of inventory was there at the end of 2023 in China for Kelo-Cote now and maybe at the end of 2024? We don't actually go into this kind of level of detail on inventory management, for Kelo-Cote across the markets. But, you're right. I mean, when we move into, smaller but more regular orders, we will see probably, like, one month reduction in the inventory at the end of the year. Last year, we communicated that six to eight months is an ideal level of, operation in markets like China, because it takes time to deliver products, produce products, bring the components, and anything that you go below, you are risking actually to deliver opportunities in the market, and then you might miss growth opportunities in the market if you go below certain levels of stock. Okay, so should we, should we expect that destocking to happen in the second half then, largely? The sort of the slower, slightly slower performance from your perspective in Kelo-Cote. I mean, since 2020 and 2022, we are working on destocking, as you know. I mean, it was an unusual situation in 2022 with the markets closed and inability to move products across the border, and that has progressed quite well in 2023. But we still have some more work on that, and this is the next action we took. Okay, my last one, please. You've provided some growth expectations for Kelo-Cote and Nizoral, but not Amberen. What should we be thinking about for this year? We continue to believe that Amberen is going to deliver growth, so we expect growth in 2024. And, we have seen already, like, our e-commerce sales are gaining momentum. There are new initiatives coming into it. We learn from any initiative we do. So, you know, in a company in our scale, it takes time to actually, like, get these moving, but we see a good trajectory. So, we would like to see how these add up and what we build in the coming months. So probably in our next trading update, we might share more, but at this moment, we internally feel confident that Amberen will grow. Thank you. Thanks, Charles. Paul Cuddon here from Deutsche Numis. Got a few clarification questions. I'm old enough to remember when Alliance used to kind of reduce debt by about half a turn, kind of each year. So, the going below 2x doesn't really seem sort of as much as you're capable of. So are there any other cash outflows we should be aware of in 2024? Nothing out of the ordinary. No, Paul. Okay, thank you. On the kind of move towards smaller orders, I think Charles has gone into the inventory side, but is there any potential market share loss consequences if you're not gonna be offering the kind of bigger bulk shipments to distributors? Let's not confuse the in-market sell-out and then market sell-in. So we continue to perform very strongly in market sellout. So that is the market share performance. And we see Kelo-Cote, especially in China. We perform much faster than the market growth. So that is helping us to gain share, reach new consumers, accelerate the stocking because we sell more products. The stock build is for our sales to distributors and how we can manage that in smaller, more regular ones, so that we can be better planned, sea freight shipments, all kinds of things that come with it. Okay, thank you. And just on Amberen, is your kind of growth, growth overall, or is this the same store, like for like growth? Well, okay. Go, Camillo. Well, it's both, right? It's both. I mean, it's, you know, at the moment, most of the business is happening in the e-commerce channel, and therefore, it's gonna be always like for like, right? So- Yeah. Hi there. Ed Sham from Singer's. So two questions, if I may. So maybe the first one for Nick, if you don't mind. So coming into the business with a fresh perspective, what do you see as the greatest opportunity for the business, and what do you see as the sort of the long-term barriers to that? So regarding opportunities, just to echo Camillo's points, we have great brands that are very strong from a market positioning perspective in global categories that grow. And from that perspective, I don't personally think we are fully optimizing and executing as well as we could in the markets that we're already in, but there are also markets that we're not. So from that perspective, we have plenty to go at in the markets that we're already operating in, but also for future growth in new markets. And then from a barriers perspective, for me, it's more we have a very long portfolio of brands, and that drives inefficiencies within our structures. So clearly, I'll be looking to see how we can make the most and drive efficiencies more effectively with what we're doing and optimize our time, and so we can spend more time on the bigger brands in the bigger markets. Would there be an opportunity to divest some of those brands further down the line? That's up for discussion. This is week six for me, so it's still very early. I'm looking. I'm going forensically through the whole of the business to make sure that when I come out with my new strategy, it's well thought through and fully optimized to drive growth. I'm used to driving growth and well above markets in previous roles, so that's what I've been brought in to do. Perfect, thanks. And then, just my second question: so in terms of your leverage, that's, that's 2.05 at the moment, likely to come down to below 2 by the end of the year. Typically, you've made some acquisitions when leverage falls below 2. So I'm just thinking, is there an opportunity for acquisitions this year, or is it something we should be looking sort of further down the line? And are there any learnings from Amberen to sort of shape that acquisition strategy going forward? So just cover the leverage piece. So yes, you're right. We've, when we've gone below 2x, but I think you also need to look at just the general overall interest rate environment. So I think we'll be looking to go a little lower through that. So let's just see how this year works out. And we are, as I say, as Camillo and Nick have mentioned, we're driving that consumer health piece. And so if we can get those returns doing that ourselves internally through higher investment in R&D, that's a very profitable approach to take. Perfect. Thanks. Hi there, James Orsborne from Stifel. I guess quick question, just seeing other consumer companies really be able to take quite all the pricing, but less a reduction in volume in some cases. Can you just give a bit of color around, you know, how much pricing you've taken and perhaps a bit of a dynamic on how that pricing and volume mix is going forward? It's both for us. So, yes, we have taken pricing on Kelo-Cote in key markets to reflect the realities, increasing prices, component prices. So that is regularly taking place. But we also see growth coming from volume because we are investing into marketing, we are reaching new consumers, opening new channels. So in our portfolio, it is a mixture of both. Both pricing and volume growth is important. Is that relatively balanced? Is that a fair comment? It is more balanced, yeah, at this moment. Yeah. Thank you. And then on your outlook for Kelo-Cote, what's the kind of margin implication? I know Kelo-Cote's a high margin product for you guys. How would you see that progression this year and I guess into 25, given the growth opportunity this year, and then going forward? And maybe a bit of a steer on that would be helpful. I mentioned to an earlier question from Sam, is that we will expect some gross margin expansion this year, 2024, as we're moving, as I say, move to the a new facility for manufacturing in for for Nizoral. We will also see some into next year when we've said that Kelo-Cote will return to, you know, a stronger growth position. That will again increase the margin expansion. Great. Thank you. The webcast. First question is from Martin Hall, from Hardman & Co. At the end of 2020, you paid $110 million dollars for Biogix, essentially Amberen, mostly goodwill. Now, you have written off $85 million dollars. How has so much value been destroyed, and what has gone wrong? Good morning, Martin, and hope you're well. So I think that there are a couple of situations or fact patterns that we need to take in around Biogix, which is the legal entity we acquired Amberen through. Is that when we acquired Amberen, a majority of its performance was in bricks and mortar, which played perfectly into our US setup. We were, as you say, we were then looking after the most, and it fit. The fact pattern worked very, very well within that period. And I think in the first year, we generated, you know, very, very good sales. Then COVID came along, and actually then, the move, the trend pivot, very quick pivot to e-commerce was in that menopause market, whereas we were very much a play in bricks and mortar. So it's that piece that's caused the delay. I think the thing I'd also add is that by bringing Amberen in, we've been able to then very efficiently acquire ScarAway, the remaining brand for the US rights, which you wouldn't have been able to do so efficiently had we not had that extra bandwidth, extra capability in that US function. So Martin's right. If you look at it, we have written Amberen down, but it's at a growing market. The market it's in is growing. I think Jeyan has already mentioned and described the improvements and the strengthening we have made within the US business, and we see some good, strong growth coming forward from Amberen. So we very much believe in it. Thank you, Andrew. Next question is from Dana Scully. When can we expect H1 2024 results, given it's almost over, 30 June? I think we've mentioned, I think, in the release, Cora, around AGM? Yes. Thank you. Yes, so the AGM is the twenty-ninth of July, and so we would normally have some form of trading update around that time. Thank you. Our next question is from Richard Wagg. Will there be further impairment of assets in 2024? And Richard, Richard is from Citibank. You can never say never. That's the first thing. And when you've impaired an asset, for those who understand this, you have no headroom. So if anything, your modeling changes, could be interest rates go up, or you have a higher cost coming through or something, that can put pressure on your, on the modeling. We're not anticipating any, but it can never, we can never assume that we won't have any going forward. But yeah. Thank you. Another question from Dana Scully: Why not pay even a small dividend, such as GBP 0.005, I think that is, given EPS is GBP 0.045, give an incentive to hold stock? So with the board, we've taken the decision to halt dividend. It was a signal that we gave in September, and we've retained that signal, so we've paused it. And I think we've described why we've paused it. So it's enabled to get our debt down and also to reinvest back some of that cash back into the business, and I think that's the key piece behind it. Andy Bamford from Seaforth Investors. If discount rates can have such an impact on the value of assets, what does it say about your ability to pass on inflation in prices? I think we've already covered that, actually, through a question that's already been asked around, ability to pass on. We can pass on, cost, cost increases, so increase the selling price to, our distributors. I think the other factor we need to look at is the evidential element that we now have to move into in order to recognize any cost, passing on of prices in our, in, that impairment model, and that's been under scrutiny this year. So, I think we have a good opportunity to do that, we have done in the past, and we continue to do so. Thank you. I think that's all the time we've got for questions at the moment. Maybe pass back to the management team for any closing remarks. No, I would like to thank everyone for the patience and given the delay of the audit and also the delay of this meeting. We will continue to work very hard. We have a new CEO in place. We look forward to come back to you with a much larger and more comprehensive view of our future strategy, and I want to thank everyone again. Thank you.